Emerging Targets in Non-Small Cell Lung Cancer.

The identification of molecular driver mutations in non-small cell lung cancer (NSCLC) has changed the therapeutic landscape for this disease. Over the last 20 years, a growing number of driver mutations have been identified in addition to new targeted therapies that have resulted in significant improvement in survival for a subset of patients. There is ongoing research to identify additional molecular targets and therapeutic strategies to improve outcomes in a greater percentage of patients with lung cancer. This review aims to highlight new therapeutic strategies targeting known driver mutations and data regarding emerging molecular targets for the treatment of NSCLC.